|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GOLPH3L |
Gene summary for GOLPH3L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GOLPH3L | Gene ID | 55204 |
| Gene name | golgi phosphoprotein 3 like | |
| Gene Alias | GPP34R | |
| Cytomap | 1q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q9H4A5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55204 | GOLPH3L | CCI_1 | Human | Cervix | CC | 1.10e-07 | 1.04e+00 | 0.528 |
| 55204 | GOLPH3L | CCI_3 | Human | Cervix | CC | 2.39e-10 | 6.38e-01 | 0.516 |
| 55204 | GOLPH3L | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.70e-03 | -2.88e-01 | 0.0155 |
| 55204 | GOLPH3L | HTA11_347_2000001011 | Human | Colorectum | AD | 1.82e-06 | 5.22e-01 | -0.1954 |
| 55204 | GOLPH3L | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.81e-02 | -3.17e-01 | 0.294 |
| 55204 | GOLPH3L | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.91e-02 | -4.76e-01 | 0.2585 |
| 55204 | GOLPH3L | HTA11_99999974143_84620 | Human | Colorectum | MSS | 5.73e-09 | -4.16e-01 | 0.3005 |
| 55204 | GOLPH3L | F007 | Human | Colorectum | FAP | 1.86e-02 | -2.76e-01 | 0.1176 |
| 55204 | GOLPH3L | A001-C-207 | Human | Colorectum | FAP | 4.33e-05 | -3.42e-01 | 0.1278 |
| 55204 | GOLPH3L | A015-C-203 | Human | Colorectum | FAP | 1.60e-19 | -3.82e-01 | -0.1294 |
| 55204 | GOLPH3L | A015-C-204 | Human | Colorectum | FAP | 2.47e-06 | -3.49e-01 | -0.0228 |
| 55204 | GOLPH3L | A014-C-040 | Human | Colorectum | FAP | 3.26e-05 | -5.16e-01 | -0.1184 |
| 55204 | GOLPH3L | A002-C-201 | Human | Colorectum | FAP | 2.14e-14 | -3.79e-01 | 0.0324 |
| 55204 | GOLPH3L | A001-C-119 | Human | Colorectum | FAP | 6.63e-05 | -2.94e-01 | -0.1557 |
| 55204 | GOLPH3L | A001-C-108 | Human | Colorectum | FAP | 2.20e-12 | -3.56e-01 | -0.0272 |
| 55204 | GOLPH3L | A002-C-205 | Human | Colorectum | FAP | 8.58e-23 | -4.84e-01 | -0.1236 |
| 55204 | GOLPH3L | A001-C-104 | Human | Colorectum | FAP | 3.31e-06 | -3.44e-01 | 0.0184 |
| 55204 | GOLPH3L | A015-C-005 | Human | Colorectum | FAP | 4.62e-03 | -2.38e-01 | -0.0336 |
| 55204 | GOLPH3L | A015-C-006 | Human | Colorectum | FAP | 8.37e-15 | -4.33e-01 | -0.0994 |
| 55204 | GOLPH3L | A015-C-106 | Human | Colorectum | FAP | 3.02e-12 | -3.70e-01 | -0.0511 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007265910 | Cervix | CC | protein localization to plasma membrane | 73/2311 | 284/18723 | 4.95e-10 | 6.73e-08 | 73 |
| GO:19907788 | Cervix | CC | protein localization to cell periphery | 78/2311 | 333/18723 | 1.22e-08 | 9.73e-07 | 78 |
| GO:005122210 | Cervix | CC | positive regulation of protein transport | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
| GO:190495110 | Cervix | CC | positive regulation of establishment of protein localization | 73/2311 | 319/18723 | 9.69e-08 | 5.25e-06 | 73 |
| GO:000690010 | Cervix | CC | vesicle budding from membrane | 20/2311 | 61/18723 | 2.50e-05 | 4.28e-04 | 20 |
| GO:00988767 | Cervix | CC | vesicle-mediated transport to the plasma membrane | 34/2311 | 136/18723 | 3.75e-05 | 5.91e-04 | 34 |
| GO:00068927 | Cervix | CC | post-Golgi vesicle-mediated transport | 28/2311 | 104/18723 | 4.31e-05 | 6.61e-04 | 28 |
| GO:00901509 | Cervix | CC | establishment of protein localization to membrane | 54/2311 | 260/18723 | 7.67e-05 | 1.05e-03 | 54 |
| GO:00481938 | Cervix | CC | Golgi vesicle transport | 58/2311 | 296/18723 | 2.24e-04 | 2.54e-03 | 58 |
| GO:00068907 | Cervix | CC | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 15/2311 | 52/18723 | 1.15e-03 | 9.39e-03 | 15 |
| GO:00068936 | Cervix | CC | Golgi to plasma membrane transport | 16/2311 | 60/18723 | 2.00e-03 | 1.46e-02 | 16 |
| GO:00619516 | Cervix | CC | establishment of protein localization to plasma membrane | 16/2311 | 60/18723 | 2.00e-03 | 1.46e-02 | 16 |
| GO:00507148 | Cervix | CC | positive regulation of protein secretion | 29/2311 | 137/18723 | 2.40e-03 | 1.70e-02 | 29 |
| GO:00430016 | Cervix | CC | Golgi to plasma membrane protein transport | 12/2311 | 40/18723 | 2.44e-03 | 1.71e-02 | 12 |
| GO:00160506 | Cervix | CC | vesicle organization | 54/2311 | 300/18723 | 2.71e-03 | 1.85e-02 | 54 |
| GO:00070304 | Cervix | CC | Golgi organization | 32/2311 | 157/18723 | 2.78e-03 | 1.87e-02 | 32 |
| GO:00481944 | Cervix | CC | Golgi vesicle budding | 5/2311 | 10/18723 | 4.20e-03 | 2.58e-02 | 5 |
| GO:0072659 | Colorectum | AD | protein localization to plasma membrane | 122/3918 | 284/18723 | 2.86e-17 | 1.49e-14 | 122 |
| GO:1990778 | Colorectum | AD | protein localization to cell periphery | 129/3918 | 333/18723 | 5.51e-14 | 1.15e-11 | 129 |
| GO:0090150 | Colorectum | AD | establishment of protein localization to membrane | 100/3918 | 260/18723 | 6.01e-11 | 6.33e-09 | 100 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GOLPH3L | SNV | Missense_Mutation | rs150623963 | c.263G>A | p.Arg88Gln | p.R88Q | Q9H4A5 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GOLPH3L | insertion | In_Frame_Ins | novel | c.643_644insACAAAA | p.Pro215delinsHisLysThr | p.P215delinsHKT | Q9H4A5 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| GOLPH3L | insertion | In_Frame_Ins | novel | c.368_369insATTCACAATACCCAAAATGTG | p.Leu123_Lys124insPheThrIleProLysMetTrp | p.L123_K124insFTIPKMW | Q9H4A5 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| GOLPH3L | SNV | Missense_Mutation | c.122N>G | p.Ser41Cys | p.S41C | Q9H4A5 | protein_coding | deleterious(0.03) | benign(0.003) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| GOLPH3L | SNV | Missense_Mutation | novel | c.175G>T | p.Asp59Tyr | p.D59Y | Q9H4A5 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| GOLPH3L | SNV | Missense_Mutation | novel | c.602A>C | p.Lys201Thr | p.K201T | Q9H4A5 | protein_coding | tolerated(0.06) | benign(0.301) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| GOLPH3L | SNV | Missense_Mutation | novel | c.760N>A | p.Ala254Thr | p.A254T | Q9H4A5 | protein_coding | tolerated(0.23) | benign(0.114) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GOLPH3L | SNV | Missense_Mutation | novel | c.335N>A | p.Ser112Asn | p.S112N | Q9H4A5 | protein_coding | tolerated(0.13) | benign(0.021) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| GOLPH3L | SNV | Missense_Mutation | novel | c.812N>G | p.Ala271Gly | p.A271G | Q9H4A5 | protein_coding | tolerated(0.57) | benign(0.005) | TCGA-A5-A7WJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GOLPH3L | SNV | Missense_Mutation | rs781403485 | c.485N>A | p.Arg162His | p.R162H | Q9H4A5 | protein_coding | deleterious(0.04) | possibly_damaging(0.802) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |